


HEALTHCARE

## **Innovations in Diagnostics**

Next generation molecular and point-of-care diagnostics driving personalized healthcare

By Jeanette Marchant

 [Table of Contents](#)

## **Jeanette Marchant**

Jeanette Marchant is principal of JM Communications which provides consultancy services to market intelligence organizations, specialist healthcare publishers, regulatory agencies and healthcare companies. She has almost 30 years' experience in writing on international healthcare business, including four years as editor of *Clinica World Medical Device & Diagnostic News*. She is the author of numerous market reports for the pharmaceutical and medical technology industries.

Copyright © 2006 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

# Table of Contents

## Innovations in Diagnostics

<b>Executive Summary</b>	<b>10</b>	
Introduction to diagnostics	10	
Challenges and opportunities in diagnostic innovation	11	
Molecular technology innovations	12	
Innovation in infectious disease diagnostics	13	
Personalized medicine	13	
Point-of-care testing	15	
Competitive landscape	16	
<b>Chapter 1</b>	<b>Introduction to diagnostics</b>	<b>18</b>
Summary		18
Introduction		19
<b>The global IVD market</b>		<b>20</b>
Market segments		20
Market dynamics		22
Market growth		23
<b>Key IVD players</b>		<b>24</b>
Industry profile		25
<b>Overview of diagnostic technologies</b>		<b>26</b>
Immunoassays		26
Nucleic acid (NA) assays		27
Biosensors		27
Microarrays		28
<b>Future trends</b>		<b>28</b>

<b>Chapter 2</b>	<b>Challenges and opportunities in diagnostic innovation</b>	<b>32</b>
<b>Summary</b>		<b>32</b>
<b>Introduction</b>		<b>33</b>
<b>A changing healthcare environment</b>		<b>33</b>
<b>Challenges &amp; opportunities</b>		<b>34</b>
Regulatory hurdles		35
Reimbursement		37
Technology requirements		38
Connectivity		38
Communication		39
New partnerships/new players		40
<b>Chapter 3</b>	<b>Molecular technology innovations</b>	<b>44</b>
<b>Summary</b>		<b>44</b>
<b>Introduction</b>		<b>45</b>
<b>IVD technologies</b>		<b>47</b>
PCR		47
FISH		48
Arrays		49
Nanotechnology		50
DNA methylation		51
DNA biosensors		53
<b>Chapter 4</b>	<b>Innovation in infectious disease diagnostics</b>	<b>56</b>
<b>Summary</b>		<b>56</b>
<b>Introduction</b>		<b>57</b>
<b>Emerging infections</b>		<b>58</b>
Avian influenza H5N1		58
SARS		59
<b>Multiple detection of infectious agents</b>		<b>60</b>
<b>Future challenges</b>		<b>62</b>
Hospital-acquired infections		62
Gonorrhea		62
Early onset sepsis		63
Other infections		63



## Chapter 7                      Competitive landscape                      98

<b>Summary</b>	<b>98</b>
<b>Introduction</b>	<b>99</b>
<b>Key mergers &amp; acquisitions</b>	<b>99</b>
<b>Competitive landscape</b>	<b>101</b>
<b>Pharma companies with Dx divisions</b>	<b>101</b>
Roche Diagnostics	102
Diabetes Care	102
Centralized Diagnostics	103
Molecular Diagnostics	103
Near Patient Testing	104
Applied Science	104
Product Pipeline	104
Abbott	105
Diabetes Care	105
Immunodiagnosics, clinical chemistry and hematology	105
Molecular Diagnostics	106
Point-of-Care	107
<b>MedTech companies with Dx divisions</b>	<b>107</b>
Becton Dickinson	107
Diagnostics	108
Biosciences	108
<b>Dx Specialists</b>	<b>109</b>
Gen-Probe	109
Clinical Diagnostics	110
Blood Screening	111
Molecular Diagnostics	111
Inverness Medical Innovations (IMI)	113
Consumer Diagnostics Products	113
Professional Diagnostics Products	114
Research & Development	115
Acquisitions	115
Tm Bioscience	116
Human Genetics	116
Infectious disease	117
PGx	117
<b>Technology specialists</b>	<b>118</b>
Affymetrix	118
Collaborations	119
Competition	119
Nanogen	120

**Chapter 8**

**Appendix**

**124**

Index

124

# List of Figures

Figure 1.1:	IVD market segments, 2005	21
Figure 1.2:	IVD market segments projected growth, 2004-2010	23
Figure 3.3:	Orion Genomics' Second Code technology	52
Figure 5.4:	The healthcare model of the future: Personalized medicine	67
Figure 5.5:	Breast cancer management in the future	69
Figure 5.6:	From diagnostic market candidate to a product: Three development phases	75
Figure 5.7:	Potential roles of genomics in cancer	77
Figure 7.8:	New cancer marker launches	104
Figure 7.9:	Gen-Probe leads US STD market, 2002-05	110
Figure 7.10:	IMI product sales by business segment, 2005	113
Figure 7.11:	IMI's leading market position in consumer diagnostics	114

# List of Tables

Table 1.1:	Top 15 IVD companies, 2005	24
Table 2.2:	Development costs and timeframes to produce a new IVD in the US, 2006	36
Table 5.3:	Cancer markers used in Dx tests	78
Table 7.4:	Pure-play diagnostic companies and ownership of IVD companies by medical device and pharmaceutical companies	101
Table 7.5:	Roche Diagnostics sales, H1 2006	102
Table 7.6:	Gen-Probe product sales, 2005	110